RNS Number: 1679R

GSK PLC 15 July 2025

## GSK plc (the 'Company')

## Transaction notification

1.	Details of PDMR/per	son closely associated with them ('PCA')
a)	Name	Sally Jackson
b)	Position/status	SVP, Global Communications and CEO Office
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, auctioneer or auction	emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where een conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.
c)	Price(s) and volume(s	Price(s) Volume(s)
		£14.4903 1
d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-07-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/per	son closely associated with them ('PCA')
a)	Name	Dylan Jackson
b)	Position/status	PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer auctioneer or auction	, emission allowance market participant, auction platform, on monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		ction(s): section to be repeated for (i) each type of instrument; saction; (iii) each date; and (iv) each place where

	transaction(s) has be	en conducted	
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence	each ('Ordinary Shares')
b)		Acquisition of Ordinary Shares f dividends paid to shareholders o	
c)	Price(s) and volume(s)	Price(s) £14.4903	Volume(s)
d)	Aggregated information Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchange (XLON	

1.	Details of PDMR/pers	son closely associated	with them ('PCA')
a)	Name	Victoria Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D	793
3.		saction; (iii) each date	repeated for (i) each type of instrument; e; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 ½ ISIN: GB00BN7SWP63	4 pence each ('Ordinary Shares')
b)	Nature of the transaction		Shares following the re-investment of nolders on 10 July 2025.
c)	Price(s) and volume(s)	Price(s) £14.4903	Volume(s)
d)	Aggregated	N/A (single transaction)	)
u)	information		
u)	00 0		
e)	information  Aggregated volume	2025-07-11	

1.	Details of PDMR/per	rson closely associated with them ('PCA')	
a)	Name	lain Whyte	ł

u <sub>j</sub>	TWEETIC	IGHT VVIIVE		
b)	Position/status	PCA of Ms V Whyte	(Company Secretary)	
c)	Initial notification/ amendment	Initial notification		
2.	Details of the issuer auctioneer or auction		e market participant, auction pla	atform,
a)	Name	GSK plc		
b)	LEI	5493000HZTVUYLO1	D793	
3.		saction; (iii) each da	e repeated for (i) each type of ir te; and (iv) each place where	nstrument;
a)	Description of the financial instrument	Ordinary shares of 31	1/4 pence each ('Ordinary Shares')	
b)	Nature of the transaction		y Shares following the re-investment reholders on 10 July 2025.	nt of
b)		dividends paid to sha	y Shares following the re-investmen	nt of
,	transaction	dividends paid to sha ) Price(s)	y Shares following the re-investment reholders on 10 July 2025.  Volume(s)  1,290	nt of
c)	transaction  Price(s) and volume(s  Aggregated information  Aggregated volume	dividends paid to sha ) Price(s) £14.4903	y Shares following the re-investment reholders on 10 July 2025.  Volume(s)  1,290	nt of

1.	Details of PDMR/per	rson closely associated with them ('PCA')	
a)	Name	Emma Walmsley	
b)	Position/status	Chief Executive Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction	ir, emission allowance market participant, auction platfon monitor	orm,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	
3.		action(s): section to be repeated for (i) each type of inst nsaction; (iii) each date; and (iv) each place where een conducted	rument
	(ii) each type of tran	nsaction; (iii) each date; and (iv) each place where	rument
a)	(ii) each type of tran transaction(s) has be	nsaction; (iii) each date; and (iv) each place where een conducted  Ordinary shares of 31 1/4 pence each ('Ordinary Shares')	
b)	(ii) each type of tran transaction(s) has be Description of the financial instrument  Nature of the	ordinary shares of 31 ½ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63  Acquisition of Ordinary Shares following the re-investment dividends paid to shareholders on 10 July 2025.	
a)	(ii) each type of transaction(s) has be Description of the financial instrument  Nature of the transaction	ordinary shares of 31 ½ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63  Acquisition of Ordinary Shares following the re-investment dividends paid to shareholders on 10 July 2025.	

a)	Aggregated information	IWA (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-07-11
f)	Place of the transaction	London Stock Exchange (XLON)

1.	Details of PDMR/per	SO	n closely associated	with them ('PCA')
a)	Name	Di	ana Conrad	
b)	Position/status	CI	nief People Officer	
c)	Initial notification/ amendment	lni	itial notification	
2.	Details of the issuer auctioneer or auction			narket participant, auction platform,
a)	Name	G	SK plc	
b)	LEI	54	193000HZTVUYLO1D7	793
3.	Details of the transa (ii) each type of tran transaction(s) has be	sa	ction; (iii) each date	repeated for (i) each type of instrument; ; and (iv) each place where
a)	Description of the financial instrument		rdinary shares of 31 ½ IN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction			Shares following the re-investment of nolders on 10 July 2025.
c)	Price(s) and volume(s	)	Price(s)	Volume(s)
			£14.4903	1,380.565
d)	Aggregated information	N	(A (single transaction)	
	Aggregated volume Price			
e)	Date of the transaction	20	)25-07-11	
f)	Place of the transaction	Lo	ondon Stock Exchang	e (XLON)

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	James Ford
b)	Position/status	SVP and Group General Counsel, Legal and Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auc	 er, emission allowance market participant, auction platform, tion monitor
a)	Name	GSK plc

~,		p.u	
b)	LEI	5493000HZTVUYLO11	D793
3.		saction; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
a)		Ordinary shares of 31 ISIN: GB00BN7SWP6	1/4 pence each ('Ordinary Shares') 33
b)	Nature of the transaction		y Shares following the re-investment of eholders on 10 July 2025.
c)	Price(s) and volume(s)	Price(s) £14.4903	Volume(s) 2,315.664
d)	Aggregated information  Aggregated volume Price	N/A (single transactio	n)
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchar	ige (XLON)

1.	Details of PDMR/pe	erson closely associated w	vith them ('PCA')
a)	Name	Sally Jackson	
b)	Position/status	SVP, Global Communicat	tions and CEO Office
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issue auctioneer or auct		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D793	3
3.		ansaction; (iii) each date; a	peated for (i) each type of instrument and (iv) each place where
<b>3</b> .	(ii) each type of tra	ansaction; (iii) each date; a been conducted	
a)	(ii) each type of tra transaction(s) has Description of the	onsaction; (iii) each date; a been conducted  Ordinary shares of 31 1/4 p ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')  nares following the re-investment of
	(ii) each type of tra transaction(s) has a Description of the financial instrument	Ansaction; (iii) each date; a been conducted  Ordinary shares of 31 1/4 p ISIN: GB00BN7SWP63  Acquisition of Ordinary St dividends paid to sharehole	pence each ('Ordinary Shares')  nares following the re-investment of
a) b)	(ii) each type of tra transaction(s) has  Description of the financial instrument  Nature of the transaction	Ansaction; (iii) each date; a been conducted  Ordinary shares of 31 1/4 p ISIN: GB00BN7SWP63  Acquisition of Ordinary St dividends paid to sharehole	pence each ('Ordinary Shares')  nares following the re-investment of liders on 10 July 2025.
a) b)	(ii) each type of tra transaction(s) has  Description of the financial instrument  Nature of the transaction	Ansaction; (iii) each date; a been conducted  Ordinary shares of 31 ½ p ISIN: GB00BN7SWP63  Acquisition of Ordinary St dividends paid to sharehol  (s) Price(s)	pence each ('Ordinary Shares')  mares following the re-investment of liders on 10 July 2025.  Volume(s)

e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchange (XLON)	

1.	Details of PDMR/per	son closely associated v	vith them ('PCA')
a)	Name	Dylan Jackson	
b)	Position/status	PCA of Sally Jackson (S' Office)	VP, Global Communications and CEO
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction		arket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D79	3
3.		saction; (iii) each date;	peated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S dividends paid to shareho	hares following the re-investment of olders on 10 July 2025.
c)	Price(s) and volume(s	) Price(s)	Volume(s)
		£14.4903	156.971
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchange	(XLON)

1.	Details of PDMR/p	erson closely associated with them ('PCA')
a)	Name	David Redfern
b)	Position/status	President Corporate Development
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	er, emission allowance market participant, auction platform, tion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		saction(s): section to be repeated for (i) each type of instrument; ansaction: (iii) each date: and (iv) each place where

	transaction(s) has be	en conducted	(, этэн р.тээээ
a)		Ordinary shares of 31 ISIN: GB00BN7SWP6	1/4 pence each ('Ordinary Shares') 33
b)			y Shares following the re-investment of eholders on 10 July 2025.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4903	7,028.653
d)	Aggregated information	N/A (single transactio	n)
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchar	nge (XLON)

1.	Details of PDMR/pers	SOI	n closely associated	l with ther	m ('PCA')
a)	Name	Re	egis Simard		
b)	Position/status	Pr	esident, Global Supp	ly Chain	
c)	Initial notification/ amendment	lni	tial notification		
2.	Details of the issuer, auctioneer or auctio			market pa	rticipant, auction platform,
a)	Name	G	SK plc		
b)	LEI	54	93000HZTVUYLO1D	793	
3.	Details of the transac (ii) each type of tran- transaction(s) has be	sa	ction; (iii) each date		for (i) each type of instrument; each place where
a)	Description of the financial instrument		rdinary shares of 31 ½ IN: GB00BN7SWP63		ch ('Ordinary Shares')
b)	Nature of the transaction		equisition of Ordinary vidends paid to share		owing the re-investment of 10 July 2025.
c)	Price(s) and volume(s)		Price(s)		Volume(s)
	1 110(0) 0111111111111111111111111111111				
			£14.4903		2,929.122
d)	Aggregated information	N/	£14.4903  A (single transaction)		2,929.122
d)	Aggregated	N			2,929.122
d) e)	Aggregated information  Aggregated volume				2,929.122

1.	Details of PDMR/pers	son closely associate	ed with them ('PCA')
a)	Name	Philip Thomson	
b)	Position/status	President, Global Affa	airs
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auctio		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1I	D793
3.	(ii) each type of tran	saction; (iii) each da	e repeated for (i) each type of instrument; te; and (iv) each place where
	transaction(s) has be	en conducted	
a)	Description of the financial instrument		1/4 pence each ('Ordinary Shares') 63
a) b)	Description of the financial instrument	Ordinary shares of 31 ISIN: GB00BN7SWP6 Acquisition of Ordinar	
,	Description of the financial instrument  Nature of the	Ordinary shares of 31 ISIN: GB00BN7SWP6 Acquisition of Ordinar dividends paid to shar	y Shares following the re-investment of
b)	Description of the financial instrument  Nature of the transaction	Ordinary shares of 31 ISIN: GB00BN7SWP6 Acquisition of Ordinar dividends paid to shar	y Shares following the re-investment of reholders on 10 July 2025.
b)	Description of the financial instrument  Nature of the transaction	Ordinary shares of 31 ISIN: GB00BN7SWP6 Acquisition of Ordinar dividends paid to shar	y Shares following the re-investment of reholders on 10 July 2025.  Volume(s)  2,401.114
b)	Description of the financial instrument  Nature of the transaction  Price(s) and volume(s)  Aggregated	Ordinary shares of 31 ISIN: GB00BN7SWP6 Acquisition of Ordinary dividends paid to share  Price(s) £14.4903	y Shares following the re-investment of reholders on 10 July 2025.  Volume(s)  2,401.114
b)	Description of the financial instrument  Nature of the transaction  Price(s) and volume(s)  Aggregated information  Aggregated volume	Ordinary shares of 31 ISIN: GB00BN7SWP6 Acquisition of Ordinary dividends paid to share  Price(s) £14.4903	y Shares following the re-investment of reholders on 10 July 2025.  Volume(s)  2,401.114

\_\_\_

L

1.	Details of PDMR/pe	erson closely associated with them ('PCA')
a)	Name	Kate Thomson
b)	Position/status	PCA of Philip Thomson (President, Global Affairs)
c)	Initial notification/ amendment	Initial notification
2.	Details of the issue auctioneer or auct	r, emission allowance market participant, auction platform, ion monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.		action(s): section to be repeated for (i) each type of instrument; insaction; (iii) each date; and (iv) each place where been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63

b)		Acquisition of Ordinary Sh dividends paid to sharehol	nares following the re-investment of ders on 10 July 2025.
c)	Price(s) and volume(s)	Price(s) £14.4903	Volume(s) 122.458
d)	Aggregated information  Aggregated volume Price	N/A (single transaction)	
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exchange (	(XLON)

1.	Details of PDMR/per	son closely associa	ted with them ('PCA')
a)	Name	Deborah Waterhous	9
b)	Position/status	CEO, ViiV Healthca	re and President, Global Health, GSK
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction		e market participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO	1D793
3.	Details of the transa (ii) each type of tran transaction(s) has be	saction; (iii) each d	oe repeated for (i) each type of instrument; ate; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 3 ISIN: GB00BN7SWF	1 ¼ pence each ('Ordinary Shares') 263
b)	Nature of the transaction		ary Shares following the re-investment of areholders on 10 July 2025.
c)	Price(s) and volume(s	) Price(s)	Volume(s)
		£14.4903	1,432.489
d)	Aggregated information	N/A (single transact	on)
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the transaction	London Stock Exch	ange (XLON)

a) Name Tony Wood	1.	Details of PDN	MR/person closely associated with them ('PCA')	
	a)	Name	Tony Wood	

b)	Position/status	Chief Scientific Officer	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer, auctioneer or auction		narket participant, auction platform,
a)	Name	GSK plc	
b)	LEI	5493000HZTVUYLO1D7	93
3.		saction; (iii) each date:	epeated for (i) each type of instrument; and (iv) each place where
a)	Description of the financial instrument	Ordinary shares of 31 1/4 ISIN: GB00BN7SWP63	pence each ('Ordinary Shares')
b)	Nature of the transaction	Acquisition of Ordinary S dividends paid to shareh	Shares following the re-investment of olders on 10 July 2025.
c)	Price(s) and volume(s)	Price(s)	Volume(s)
		£14.4903	1,422.165
d)	Aggregated information	N/A (single transaction)	
	Aggregated volume Price		
e)	Date of the transaction	2025-07-11	
f)	Place of the	London Stock Exchange	e (XLON)

1.	Details of PDMR/per	rson closely associated with them ('PCA')	
a)	Name	Victoria Whyte	
b)	Position/status	Company Secretary	
c)	Initial notification/ amendment	Initial notification	
2.	Details of the issuer auctioneer or auction	l r, emission allowance market participant, auction platform, on monitor	
a)	Name	GSK plc	
	+		_
b)	LEI	5493000HZTVUYLO1D793	
<b>3.</b>	Details of the transa	action(s): section to be repeated for (i) each type of instrumensaction; (iii) each date; and (iv) each place where	nt;
,	Details of the transa	action(s): section to be repeated for (i) each type of instrumensaction; (iii) each date; and (iv) each place where	nt;
3.	Details of the transa (ii) each type of tran transaction(s) has be	Inction(s): section to be repeated for (i) each type of instrumensaction; (iii) each date; and (iv) each place where een conducted  Ordinary shares of 31 1/4 pence each ('Ordinary Shares')	nt;
<b>3.</b> a)	Details of the transa (ii) each type of tran transaction(s) has be Description of the financial instrument	action(s): section to be repeated for (i) each type of instrumensaction; (iii) each date; and (iv) each place where een conducted  Ordinary shares of 31 ½ pence each ('Ordinary Shares')  ISIN: GB00BN7SWP63  Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 10 July 2025.	

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price	
e)	Date of the transaction	2025-07-11
f)	Place of the transaction	London Stock Exchange (XLON)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscange:mscang

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <a href="Privacy Policy">Privacy Policy</a>.

END

DSHSFDFDIEISEFW